Prothena Corp (PRTA): PRX002 - Excellent single dose results r...

Reply Private New

Next 10 Prev Next

Send PM Follow Ignore

Followers	11
Posts	658
Boards Moderated	0
Alias Born	12/21/2004

djpope

Re: None

Wednesday, 06/17/2015 9:52:44 AM

Wednesday, June 17, 2015 9:52:44 AM

PRX002 - Excellent single dose results released today

Conference call at 5:30 PM EDT. See link below for further details.

Enjoy dp

http://finance.yahoo.com/news/prothena-presents-clinical-results-demonstrating-110000092.html

Prothena Presents Clinical Results Demonstrating Robust, Rapid Reduction in Levels of Free Serum Alpha-Synuclein of Up to 96% After Single Dose of PRX002, Novel Protein Immunotherapy for Parkinson's Disease

Prothena Corporation plc GlobeNewswire

PRX002 was Safe and Well Tolerated; Phase 1 Single Ascending Dose Study Objectives Met
Dose- and Time-Dependent, Statistically Significant Reduction in Free Serum Alpha-Synuclein within One Hour of PRX002 Administration
Data Presented in Late Breaking Poster Session at 19th International Congress of Parkinson's Disease and Movement Disorders (Abstract #LBA19) in San Diego
Investor Conference Call and Webcast Today at 5:30 p.m. EDT